Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data
about
Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data
description
2016 nî lūn-bûn
@nan
2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Ofatumumab plus chlorambucil a ...... al antibodies association data
@ast
Ofatumumab plus chlorambucil a ...... al antibodies association data
@en
Ofatumumab plus chlorambucil a ...... al antibodies association data
@nl
type
label
Ofatumumab plus chlorambucil a ...... al antibodies association data
@ast
Ofatumumab plus chlorambucil a ...... al antibodies association data
@en
Ofatumumab plus chlorambucil a ...... al antibodies association data
@nl
prefLabel
Ofatumumab plus chlorambucil a ...... al antibodies association data
@ast
Ofatumumab plus chlorambucil a ...... al antibodies association data
@en
Ofatumumab plus chlorambucil a ...... al antibodies association data
@nl
P2093
P2860
P356
P1476
Ofatumumab plus chlorambucil a ...... al antibodies association data
@en
P2093
Alessandra Tedeschi
Anna Maria Frustaci
Maddalena Mazzucchelli
Marco Montillo
Paola Picardi
Roberto Cairoli
P2860
P304
P356
10.1177/2040620716648567
P407
P577
2016-08-01T00:00:00Z